期刊文献+

小剂量结核菌素与羟基喜树碱交替膀胱灌注预防膀胱癌术后复发的临床观察

Clinical observation of low-dose BCG and hydroxycamptothecin alternately intravesical instillation to prevent the post-operative recurrence of bladder cancer
原文传递
导出
摘要 目的 探讨羟基喜树碱(HCPT)、小剂量结核菌素(BCG)交替膀胱灌注预防膀胱癌术后复发的效果.方法 选择312例膀胱癌术后患者,随机分为HCPT和小剂量BCG交替膀胱灌注组(A组)、HCPT膀胱灌注组(B组)各156例.A组:术后第7d用HCPT 10mg+生理盐水20 mL膀胱灌注,第14d用BCG 10mg+生理盐水40mL膀胱灌注;之后每隔3d交替灌注1次,至术后第56d;术后第63d开始,每隔1周交替灌注1次,各灌注8次;术后第183d开始,每隔15d交替灌注1次,各灌注8次;术后第438d开始,每隔1个月交替灌注1次至术后2年.B组:自术后第7d起,用HCPT 10mg+生理盐水20mL膀胱灌注,每周灌注1次,至术后第56d;术后第70d开始,每隔2周灌注1次,共8次;术后第198d开始,每隔1个月灌注1次,共8次;术后第468d开始,每隔2个月灌注1次至术后2年.各种药物灌注剂量同首次灌注.分别观察两组0~18、19 ~24、25 ~60个月的肿瘤复发率及毒副反应.结果 随访60个月,A组复发率分别为0(0~18个月)、3.21%(19 ~24个月)、18.67%(25~60个月),B组分别为11.54%、7.10%、20.13%,两组0~18个月的复发率比较差异有统计学意义(P<0.05);两组均出现非细菌性膀胱炎、血尿、低热、血象异常等毒副反应,但两组比较差异均无统计学意义(P>0.05).结论 HCPT和小剂量BCG交替膀胱灌注预防膀胱癌术后复发效果较好,毒副反应较轻且发生率低. Objectives To investigate the effect of low dose tuberculin (BCG) and hydroxycamptothecin (HCPT) alternately intravesical instillation after the post-operative recurrence of bladder cancer.Methods 312 cases of bladder cancer after operation were randomly divided into the group of alternating intravesical instillation of HCPT and low-dose BCG (A group) and HCPT group(B group),156 cases in each group.Group A:HCPT 10mg added to normal saline 20ml were vesically irrigated 7 days after operation,BCG 10mg added to normal saline 40ml were vesically irrigated 14 days after operation; then alternately vesical irrigation was given every other 3 day till 56 days after operation; after 63 days of operation,alternately vesical irrigated every 1 week,8 times for each drug; after 183 days of operation,altemately vesical irrigated every 15 days,8 times for each drug; after 438 days of operation,alternately vesical irrigated till 2 years post-operation.Group B:This group was infused with HCPT 10mg added to normal saline 20ml after 7 days of operation,then was given once a week to 56 days of postoperation; then once every other 2 weeks to 197 days of post-operation; once every other 1 month for 8 times; once every other 2 months till 2 years of post-operation.The total dose for each time of irrigation is the same with the first time.The Recurrence rate and side effects were observed 0 ~ 18 months,19 ~ 24months and 25 ~ 60months separately.Results After 60 months of follow-up,the recurrence rate was 0 (0 ~ 18months),3.21% (19 ~ 24 months) ; 18.67% (25 ~ 60months) for group A,and 11.54%,7.10% and 20.13% for group B separately.The difference between the recurrence rate of the two groups from 0-18 months was significant in statistics (P 〈 0.05).Nonbacterial cystitis,hema turia,fever and abnormal routine blood test results were observed in both groups,but the difference was not significant in statistics(P 〉 0.05).Conclusions Low dose tuberculin (BCG) and hydroxycamptothecin alternately intravesical therapy has a good effect on post-operation recurrence prevention with fewer and slighter side effects.
出处 《国际泌尿系统杂志》 2014年第2期190-193,共4页 International Journal of Urology and Nephrology
基金 基金项目:沧州市科学技术研究与发展指导计划项目0ZD73)
关键词 膀胱肿瘤 结核菌素 喜树碱 Urinary Bladder Neoplasms Tuberculin Camptothecin
  • 相关文献

参考文献9

  • 1龚旻,伊庆同,叶敏,胡巍,顾建军,陈楚红,王华,郭建华,祝风明.膀胱内单纯化疗与联合免疫化疗预防膀胱癌复发的疗效分析[J].临床泌尿外科杂志,2008,23(8):574-576. 被引量:6
  • 2苏昀,姚茂银,张忠林,苑章,杨建军,柳靖,胡向农.羟基喜树碱及卡介苗膀胱灌注预防膀胱癌术后复发临床观察[J].中国肿瘤临床,2001,28(12):910-911. 被引量:13
  • 3陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011:3465.
  • 4Tinazzi E,Ficarra V,Simeoni S,et al.Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma:a systematic review[J].Rheumatol Int,2006,26(6):481-488.
  • 5Hameed A,Sezian N,Thwaini A.Bladder contracture:review for intravesical bacillus Calmette-Guerin complication[J].Can J Urol,2007,14(6):3745-3749.
  • 6Meyer JP,Persad R,Gillatt DA.Use of bacille Calmette-Guérin in superficial bladder cancer[J].Postgrad Med J,2002,78(922):449-454.
  • 7Sylvester R J,Oosterlinek W,van der Meijden AP.A single immediate postoperative instilation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer:a meta-analysis of published results of randomized clinical trials[J].JUrol,2004,171 (6 pt 1):2186-2190.
  • 8刘锁民,刘屹立.丝裂霉素与卡介苗联合灌注预防表浅膀胱癌术后复发的疗效观察[J].中国厂矿医学,2007,20(3):205-206. 被引量:4
  • 9郭应禄,周利群等译.Alanj J,et al原著.坎贝尔-沃尔什泌尿外科学[M].北京:北京大学医学出版社,2009.

二级参考文献16

  • 1杨德安,李慎勤.表浅型膀胱肿瘤术后复发的预防[J].临床泌尿外科杂志,1996,11(2):123-125. 被引量:12
  • 2Lamm DL.BCG in perspective:advances in the treatment of superficial bladder cancer[J].Eur Urol,1995,27(Suppl 1):2-8.
  • 3Heney NM,Ahmed S,Flanagan MJ,et al.Superficial blader cancer:progression and recurrence[J].J Urol,1983,130(6):1083-1086.
  • 4Tolley DA,Parmar MK,Grigor KM,et al.The effect of intravesical mitomycin C on recurence of newly diagnosed superficial bladder cancer:a further report with 7 years of follow-up[J].J Urol,1996,155(4):1233-1238.
  • 5Klan R,Loy V,Huland H.Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder[J].J Urol,1991,146(2):316-318.
  • 6Thrasher JB,Crawford ED.Complications of intravesical chemotherapy[J].Urol Clin North Am,1992,19(3):529-539.
  • 7Bohle A,Jocham D,Bock PR.Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer:a formal meta-analysis of comparative studies on recurrence and toxicity[J].J Urol,2003,169(1):90-95.
  • 8Malkowicz SB.Management of superficial bladder cancer.In:Walsh PC,Retik AB,Vaughan ED,et al.Campbell's Urology[M].8th ed.Philadelphia:WB Saunders,2002.2796.
  • 9Green D F, Robinson M R G, Glashan R, et al. Does intravesical chemotheraphy prevent invasive bladder cancer[J]? J Urol, 1984, 131:33-35.
  • 10Teruaki A O, Toyoaki Uchida, Yokoyama E L, et al. Prophylatic combination therapy after TUR of superficial bladder cancer[J]. Acta Urol Jpn, 1993, 39:987-989.

共引文献877

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部